<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00280618</url>
  </required_header>
  <id_info>
    <org_study_id>L_9202</org_study_id>
    <nct_id>NCT00280618</nct_id>
  </id_info>
  <brief_title>Oxaliplatin in Unresectable Hepatocellular Carcinoma</brief_title>
  <official_title>Phase II Study of Eloxatin + 5-Fluorouracil/Leucovorin in Patients With Unresectable Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary:

        -  To determine the Tumor Response Rate of patients with hepatocellular carcinoma treated
           with the combination chemotherapy of Eloxatin+5-Fluorouracil/Leucovorin

      Secondary:

        -  Safety and tolerability of this regimen in these patients
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Tumor Progression (TTP) and Response Rate: evaluated by RECIST</measure>
    <time_frame>During the Study Conduct</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events collections and evaluation</measure>
    <time_frame>From the signature of the informed consent up to the end of the study</time_frame>
  </secondary_outcome>
  <condition>Carcinoma, Hepatocellular</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have histologically confirmed hepatocellular carcinoma

          -  Patients must have measurable disease by CT scan

          -  Patients with unresectable, recurrent or metastatic disease may be chemonaive or may
             be previously treated by chemotherapy.

          -  The period of washout of prior chemotherapy must be greater than 4 weeks from date of
             randomization. The prior chemotherapy should not include platinum compounds.

          -  WHO performance status: 0 to 2

          -  Patients must have adequate organ and marrow function as defined below:

               -  Leukocytes : ≥ 3,000/μl

               -  Absolute neutrophil count :≥ 1,500/μl

               -  Platelets : ≥ 80,000/μl

               -  Total bilirubin : &lt; 3.0g/dl

               -  ASAT/ALAT : ≤ 3 times the upper normal limits of the institute

               -  Creatinine : &lt; 120μmol/l

          -  Patients with no evidence of clinically significant neuropathy.

        Exclusion Criteria:

          -  Documented allergy to platinum compound or to others study's drugs

          -  Pregnant or lactating women or women of childbearing potential (e.g. not using
             adequate contraception)

          -  Hematological disorder or malignancies

          -  Metastasis to central nervous system

          -  Other serious illness or medical conditions:

               -  Active infectious disease

               -  Congestive heart failure, or angina pectoris. Previous history of myocardial
                  infarction within 1 year from study entry; uncontrolled hypertension or
                  arrhythmia.

          -  Concurrent treatment with any other anticancer therapy

          -  Concurrent treatment with other experimental drugs.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pingkuan Zhang</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2006</study_first_submitted>
  <study_first_submitted_qc>January 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2006</study_first_posted>
  <last_update_submitted>September 14, 2009</last_update_submitted>
  <last_update_submitted_qc>September 14, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2009</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

